Innovation Lifecycle Management: Health Technology Assessment (HTA)

By completely disclosing ambiguity, health technology assessments (HTAs) attempt to assist avoid clinical, social, financial, and ethical errors. To the array of choices for numerical assumptions than to quantify uncertainty for “qualitative” hypotheses, uncertainty analyses may address the former while overlooking the latter. Patent exclusivity, as well as various components of the administrative and HTA systems, currently do a poor job of rewarding and driving innovation. However, enhanced integration of the evidence expectations of various HTA and insurance bodies, as well as, to the extent possible, integration of HTA/coverage bodies’ expectations with the prerequisites of regulatory authorities, could have a strong positive influence on value-based health-care innovations. Therefore, importance of possible HTA enhancements is hence, emphasized.